Page 3 - Rafaelg Amado News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited kingdomUnited statesRafaelg amadoChristine chiou lina zhangShaun maccoun xiaoyu chenZai lab limitedBristol myers squibbNational medical products administrationPoint therapeutics incHead of global oncology researchZai lab forwardZai labExchange commissionDrug administrationLab limited

Zejula Maintenance Decreases Progression, Death Risk in Ovarian Cancer

Frontline Zejula maintenance therapy decreased the risk of disease progression or death in patients with newly diagnosed ovarian cancer.

Rafaelg amadoLingying wuNational clinical research centerGlobal oncology researchZai labDepartment of gynecologic oncologyIncreased usePatients with ovarianGynecologic oncologyOvarian cancer

JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients

The Phase 3 PRIME study demonstrates that treatment with ZEJULA significantly extends progression-free survival versus placebo and reduces the risk of disease progression or death by 55% .

Hong kongUnited statesUnited kingdomAlina zhangShaun maccounXiaoyu chenChristine chiouRafaelg amadoHead of global oncology researchZai lab forwardZai lab limitedExchange commissionZai labLab limitedGlobal oncology researchAbout ovarian

MIL-OSI: JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients

MIL-OSI: JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomShaun maccounRafaelg amadoXiaoyu chenAlina zhangChristine chiouZai lab forwardZai labExchange commissionHead of global oncology researchZai lab limitedRecommended sponsor painted moonOriginal artwork directlyGlobal oncology research

MIL-OSI: Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer

MIL-OSI: Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomRafaelg amadoAlina zhangRui hua xuChristine chiouGastroenterol hepatolShaun maccoun xiaoyu chenZai labZai lab limitedHead of global oncology researchDrug administrationChina centerZai lab forwardExchange commission